| Home | E-Submission | Sitemap | Contact Us |  
J Korean Cancer Assoc > Volume 26(5); 1994 > Article
Journal of the Korean Cancer Association 1994;26(5): 841-847.
Hodgkin 씨 병 환자에서 과량의 Vinblastine 투여후 발생한 독성
한상국, 김용주, 한지연, 강진형, 문한림, 홍영선, 김훈교, 이경식, 김동집
Serious Toxicities Induced by Vinblastine Overdose in a Patient with Relapsed Hodgkin's Disease
Sang Kook Han, Yong Joo Kim, Ji Youn Han, Jin Hyoung Kang, Han Lim Moon, Young Seon Hong, Hoon Kyo Kim, Kyung Shik Lee, Dong Jip Kim
Vinblastine, referred to as a vinka alkaloid, has been used as a component of the various chemotherapeutic regimens in the treatment of nonseminomatous testicular carcinoma, chorioearcinoma, non-small cell lung carcinoma, bladder cancer, head and neck cancer and cervical cancer. Vinblastine has been used as a main component of ABVD combination therapy for the patients with advanced Hodgkins disease who relapsed after therapy with the MOPP regimen. The major adverse effects of usual dosage of vinblatine are myelosuppression, nausea, vomiting, local effects(phlebitis, necrosis when extravasated), and peripheral and autonomic neuropathies. We experienced the life threatening toxicities including bone marrow suppression, oral mucositis, peripheral neuropathies and paralytic ileus in a 41-year-old male patient with re- lapsed Hodgkins disease who was errorneously treated with 50 mg of vinblastine. The patient was recovered completely with intensive supportive treatment.
Key words: Vinblastine overdose, Hodgkins disease
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
Related articles
Ketoconazole Treatment of Oral Candidiasis in Patients with Neoplastic Disease  1985 ;17(1)
Conventional Treatments in Patients with Hodgkin's Disease  1999 August;31(4)
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI